Disease: HER2 gene amplification ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 Biomarker disease BEFREE The JNMF detected known associations between biomarkers and drugs such as BRAF mutation with PLX4720 and HER2 amplification with lapatinib. 29950679 2018
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 Biomarker disease BEFREE Patients were divided into 4 subgroups: R (RAS mutant), B (BRAF<sup>V600E</sup> mutant), H (wild-type RAS/BRAF with HER2 amplification), and W (wild-type RAS/BRAF without HER2 amplification). 29866615 2018
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 Biomarker disease BEFREE It has also been shown that RAS and BRAF wild type metastatic CRC enriches for the presence of HER2 amplification. 30100092 2018
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE Molecular characteristics exploited within these studies were MGMT promoter hypermethylation (48.7%), HER2 amplification (28.8%), BRAF <sup>V600E</sup> mutation (20%), and novel gene fusions involving ALK or NTRK (2.5%). 28669023 2017
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE Of 142 RAS and BRAF wild-type tumors, we observed 7 cases (4.9%) of HER2 amplification by SISH. 28223103 2017
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE Our results support that subgrouping using PIK3CA and BRAF mutation or HER2 amplification status, in addition to KRAS mutation status, is helpful for managing advanced CRC patients. 26991109 2016
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE An increasing number of molecular alterations have been more recently hypothesized to be involved in resistance to anti-EGFR mAbs in CRC: mutations in BRAF, NRAS and PIK3CA, loss of expression of PTEN and, now, activation of HER2 signaling through HER2 gene amplification and/or increased heregulin stimulation. 23281932 2013
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 Biomarker disease BEFREE The most prevalent biomarkers in pulmonary adenocarcinoma were KRAS mutations (29%), loss of PTEN expression (18%), EGFR mutations (9%), HER2 amplification (5%) and BRAF mutations (3%), while the prevalence of ALK translocations and PIK3CA mutations was extremely low. 23876834 2013
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE Mutually exclusive genetic aberrations were detected in 15 of 27 (56%) tumors, including 2 (7%) mutations in BRAF, 5 (19%) mutations in PIK3CA, and 8 (30%) cases of HER2 gene amplification. 23186780 2013
CUI: C1512127
Disease: HER2 gene amplification
HER2 gene amplification 		0.100 GeneticVariation disease BEFREE EGFR and HER2 gene amplification was observed in 5.3% and 26.3%, respectively, of KRAS and BRAF wild type colorectal cancer patients. 20563851 2011